Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1320251
European Journal of Endocrinology, Vol 132, Issue 3, 251-263
Copyright © 1995 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eriksen, E. F.
Right arrow Articles by Charles, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Eriksen, E. F.
Right arrow Articles by Charles, P.

New markers of bone metabolism: clinical use in metabolic bone disease

Erik Fink Eriksen, Kim Brixen and Peder Charles

Bone remodeling constitutes the life-long renewal process of bone whereby the mechanical integrity of the skeleton is preserved. It implies the continuous removal of bone (bone resorption) followed by synthesis of new bone matrix and subsequent mineralization (bone formation). Moreover, bone remodeling is an integral part of the calcium homeostatic system together with the kidneys and the gut. The ever ongoing removal of old bone by osteoclastic resorption and subsequent coupled osteoblastic formation of new bone leads to liberation of calcium and matrix constituents into the serum. The matrix constituents liberated into the blood during bone resorption can be used as markers of bone resorption in serum or urine and components liberated during osteoblastic matrix synthesis are putative markers of bone formation.

Extensive research over the last 10 years has characterized a wide variety of new markers of cellular activity in bone (Table 1). Serum and urine levels of these




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
J. L. Gonzalez-Calvin, F. Gallego-Rojo, R. Fernandez-Perez, F. Casado-Caballero, E. Ruiz-Escolano, and E. G. Olivares
Osteoporosis, Mineral Metabolism, and Serum Soluble Tumor Necrosis Factor Receptor p55 in Viral Cirrhosis
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4325 - 4330.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Rix, P. Eskildsen, and K. Olgaard
Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure
Nephrol. Dial. Transplant., April 1, 2004; 19(4): 870 - 876.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Lomeo and A. Bolner
Stability of Several Biochemical Markers of Bone Metabolism
Clin. Chem., August 1, 2000; 46(8): 1200 - 1202.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. J. Colman, J. W. Kemnitz, M. A. Lane, D. H. Abbott, and N. Binkley
Skeletal Effects of Aging and Menopausal Status in Female Rhesus Macaques
J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4144 - 4148.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Roberts, W. Lee, R. C. Cuneo, J. Wittmann, G. Ward, R. Flatman, B. McWhinney, and P. E. Hickman
Longitudinal Study of Bone Turnover after Acute Spinal Cord Injury
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 415 - 422.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Jodar, M. Munoz-Torres, F. Escobar-Jimenez, M. Quesada, J. D. Luna, and N. Olea
Antiresorptive Therapy in Hyperthyroid Patients: Longitudinal Changes in Bone and Mineral Metabolism
J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1989 - 1994.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 European Society of Endocrinology.